Kornimate/medical-research-clean huggingface dataset:
integrative risk reduction and treatment for teen substance use problems and ptsd

Conditions: PTSD; Alcohol Use Disorders; Substance Use Disorders

Summary: adolescents receiving rrft and their caregivers will report significantly fewer substance use problems (quantity of use, frequency of use, and abuse symptoms) during treatment and follow-up than control adolescents who receive treatment as usual (tau). adolescents receiving rrft and their caregivers will report improvement in empirically-demonstrated risk and protective factors for substance use and abuse at the individual level (e.g., coping) and at each level of an adolescent's ecology (e.g., increased number of positive family activities, reduced family conflict, reduced number of peers who use drugs, improved school attendance, increased involvement in pro-social community activities) during treatment and follow-up than control adolescents who receive tau. adolescents receiving rrft will experience less ptsd symptoms (per youth and caregiver reports) during treatment and follow-up than control adolescents who receive tau. adolescents receiving rrft will report engaging in fewer risky sexual behaviors (e.g., increased condom use, fewer partners) during treatment and follow-up than control adolescents who receive tau. changes during treatment in family relations (familial cohesiveness and conflict, satisfaction with caregiver-youth relationship) and parenting practices (monitoring) will mediate changes in substance use. changes during treatment in emotional reactivity will mediate changes in ptsd symptoms.

see above.

Eligibility criteria:
inclusion criteria: * 1) 13-18 years old; * 2) presenting to lcc/hh for evaluation or treatment; * 3) report having experienced ipv in their lifetime, including: csa, defined as forced or unwanted: (a) vaginal or anal penetration by an object, finger, or penis; (b) oral sex; (c) touching of the respondent's breasts or genitalia; or (d) respondents' touching of another person's genitalia; cpa, defined as having been (a) attacked or threatened with a gun, knife, or some other weapon; (b) attacked by another person with perceived intent to kill or seriously injure; (c) beaten and injured (i.e., "hurt pretty badly") by another person; (d) spanked so forcefully that it resulted in sustained welts or bruises or required medical care; or (e) cut, burned, or tied up by a caregiver as a punitive consequence; exposure to domestic violence; and being victim of or bearing witness to community violence. * 4) have a memory of the incident(s); * 5) five or more dsm-iv ptsd symptoms; * 6) substance use, defined as alcohol or illicit drug use in the past 90 days per self-report and/or urine drug screen or breathalyzer. exclusion criteria: * 1) previously identified as having a pervasive developmental disability or moderate to severe mental retardation; * 2) actively suicidal or homicidal; * 3) reports active psychotic disorder
interventional radiology liver directed therapies and hypofractionated image-guided radiation therapy in veteran and non-veteran, non-surgical hepatocellular carcinoma patients

Conditions: Liver Cancer

Summary: this is a research study to evaluate change in quality of life, as defined by the european organization for research and treatment of cancer quality of life questionnaire core-30 (eortc c-30), from baseline to 1 month post treatment in two patient cohorts receiving interventional radiology liver directed therapies or hypofractionated image-guided radiation therapy.


Eligibility criteria:
inclusion criteria: * hcc diagnosed either by histology/pathology or liver imaging reporting and data system (lirads 5 per the acr's lirads criteria 10) by ct or mri * patient is 18 years or older * ecog performance status of 0-2 * child pugh score a5, a6, b7 or b8 (see appendix) * lesion ≤ 5cm in size * ≤ 3 lesions in the liver to be treated on protocol * lesion amenable to treatment with both interventional radiology liver directed therapies and higrt. exclusion criteria: * child pugh score b9 or class c * fluctuating ascites * inability to complete baseline quality of life survey forms * concurrent administration of systemic therapy for hepatocellular carcinoma * prior liver radiation therapy is an exclusion unless subject participation is approved by the pi
female teacher's voice during teaching

Conditions: Functional Voice Disorder

Summary: two voice therapy methods are compared. activity noise levels and vocal load of teachers during teaching in primary school classrooms are evaluated. acoustic and workshop interventions are implemented in order to reduce noise level during lesson.

due to the voice disorders, teachers are a major customer group for voice therapy. the main part of the study is comparison of two voice therapy methods. there are several factors in the classroom that increase teacher's risk of voice disorders. one of the most significant is high noise level during lessons. this study explores the noise conditions the teachers are working in and how these conditions are related to the voice parameters and symptoms. finally, the study aims to determine whether classroom noise level can be lowered by improving classroom acoustics and by noise reducing workshops for teachers and pupils.

Eligibility criteria:
inclusion criteria: * female teachers or teachers of special needs children from elementary schools * voice symptoms and willingness to participate in voice therapy * mother tongue finnish * no hearing loss, no need to use a hearing aid * non-smoking * no neurological diseases * no voice therapy during past year * successful phoniatric examination with rigid laryngoscopy or nasal endoscopy exclusion criteria: * mother tongue other than finnish * need to use a hearing aid * need for medical treatment in the larynx * abnormalities of the larynx * vocal cord paresis * laryngitis * posterior hypertrophy

Keywords: voice disorder teacher's voice voice spl (voice sound pressure level) voice f0 (voice fundamental frequency) voice therapy voice accumulator activity noise classroom
ultrasound greater occipital nerve block at c2 level compared to landmark-based greater occipital nerve block

Conditions: Occipital Neuralgia; Cervicogenic Headache; Migraine Without Aura

Summary: this study will compare the analgesic benefit of a traditional landmark-guided gon block with the ultrasound-guided approach over a four week period in patients with occipital neuralgia or cervicogenic headache.

hypothesis: a novel ultrasound-guided greater occipital nerve (gon) block at the level of c2 will result in significantly lower pain scores after 4 weeks when compared with a traditional landmark-guided approach at the superior nuchal line. the greater occipital nerve (gon) has been implicated in several conditions that prompt referral to pain medicine specialists, including occipital neuralgia and cervicogenic headache. according to the international headache society, a local anesthetic block of the gon can aid in the diagnosis and treatment of occipital neuralgia. many practitioners perform gon injections using a conventional approach, relying solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line. the ambiguity of these injections poses a risk of anesthetizing adjacent structures or injecting into vessels, such as the occipital artery. in an attempt to mitigate these risks and improve the efficacy of gon injections, ultrasound has been increasingly utilized. multiple studies have demonstrated successful ultrasound-guided gon blockade at the superior nuchal line and improvement in pain scores compared to non-guided injections. the investigators' preliminary data confirms the feasibility, efficacy, and safety of an ultrasound-guided gon block technique at the level of c2, but it is not yet known whether this technique provides greater pain relief and functional outcomes compared to traditional injections.

Eligibility criteria:
inclusion criteria: 1. unilateral or bilateral headache symptoms attributed to occipital neuralgia or cervicogenic headache as defined by the international headache society's international classification of headache disorders (3rd edition beta version) 2. age 18 years and older (no upper age limit defined) 3. imaging of cervical spine within last year (either x-ray, mri or ct) exclusion criteria: 1. history of cervical spine surgery, trauma, or surgical procedure involving head or neck during the last year 2. use of new preventative medications 1 month prior or during study enrollment 3. evidence of impaired sensation in the gon dermatome region (posterior scalp to the vertex of the cranium) from neurological, dermatological, or other disease process 4. evidence of cranial defect or other anatomical abnormality near the target injection site 5. history of bleeding diathesis, coagulopathy, or current use of anticoagulant medications 6. pregnancy 7. history of adverse reaction or allergy to local anesthetic agents or corticosteroids 8. occipital nerve block within the past three months. 9. unavailability for appropriate follow-up throughout the whole duration of study
tace associated to systemic bevacizumab for the treatment of refractory liver metastases from colorectal cancer

Conditions: Liver Metastasis Colon Cancer

Summary: transarterial chemoembolization (tace) is an effective, minimally invasive therapy that is widely used for unresectable colorectal cancer liver metastases (crc-lm) treatment. chemoembolization, however, induces a hypoxic micro-environment, which increases neo-angiogenesis, and may promote early progression. for this reason, efficacy may be improved by associating tace with an angiogenesis inhibitor, such as bevacizumab. the use of folfiri associate to bevacizumab is part of clinical practice and is commonly used for the therapy of patients with crc-lm both wild type and mutant. this case-control observational study aim to compare patients treated with tace using irinotecan-loaded embolics followed by systemic bevacizumab versus patients treated with filfiri+ bevacizumab

tace is indicated for the treatment of unresectable crc_lm, patients who are refractory to systemic chemotherapy, elderly, or have a poor performance status, and is usually performed using irinotecan (iri) covalently loaded onto embolics. although chemoembolization with irinotecan-loaded embolics results in an objective response, this method creates a hypoxic micro-environment. hypoxia induces and activates the hif-1 and hif 2 hypoxia-inducible transcription factors, which promote high-level vegf expression and subsequent neo-angiogenesis. this may provide a mechanism for early relapse and progression following tace and strongly support a rational for following tace therapy with a therapeutic inhibitor of angiogenesis, such as bevacizumab. the use of folfiri associate to bevacizumab is part of clinical practice and is commonly used for the therapy of patients with crc-lm both wild type and mutant. this case-control observational study aim to compare patients treated with tace using irinotecan-loaded embolics followed by systemic bevacizumab versus patients treated with filfiri+ bevacizumab

Eligibility criteria:
inclusion criteria: * written informed consent * \>18 years old; * diagnosed with unresectable crc-lm (for reasons of anatomy, co-morbidity, patient's wishes, lack of response to standard therapy with intravenous or oral fluoropyrimidine, oxaliplatin, irinotecan or biological agents (bevacizumab, cetuximab, panitumumab); * eastern cooperative oncology group (ecog) 0-1; * measurable tumor size by mrecist \[6\]; * ≤40% liver involvement; * a life expectancy of at least 3 months, * blood biochemistry within the normal range. exclusion criteria: * contraindication for angiographic catheterization; * extensive extra-hepatic disease; * pregnancy or breast-feeding, * other severe clinical contraindications (e.g. liver failure, ascites, cardiovascular diseases and/or chronic obstructive pulmonary disease).

Keywords: liver metastases transarterial chemoembolization bevacizumab anti-angiogenesis irinotecan embolics folfiri
heart rate variability in trauma patients

Conditions: Trauma

Summary: the purpose of this study is to develop new triage tool for trauma patients based on hrv. ekg will be prospectively measured in trauma patients in two locations: in the prehospital setting (the field and during transport by helicopter) and in the hospital setting. in each case hrv will be derived from the ekg signal, will be correlated with other non-invasive signals (e.g. near infrared spectroscopy (nir), and bispectral eeg (bis)), along with other routinely measured variables (blood pressure, respiratory rate, pulse oximetry, etc), will be correlated with injury severity and day of discharge. an algorithm will be constructed using multiple linear regression. the hypotheses are: 1. reduced hrv in the field correlates with bad outcome; 2. the specificity and efficiency of hrv as a screening tool can be improved by controlling factors such as heart rate, age, gender, respiratory rate, and pulse oxygen saturation; 3. an easy to interpret hrv index can be derived that can be used for trauma triage or diagnosis.

the eligible study population will be comprised of patients who meet level 1 trauma criteria and are transported by helicopter to ryder trauma center or who are already admitted to the trauma center for presumptive traumatic brain injury. in addition to the ekg, trauma patients may also be connected to either an non-invasive nir monitor, which provides real-time information about perfusion status and/or a bispectral eeg monitor, which provides real-time information about brain metabolic activity.

Eligibility criteria:
inclusion criteria: * patients who meet level 1 trauma criteria and are transported by helicopter to ryder trauma center * an additional study population will be comprised of patients already admitted to the trauma center for presumptive traumtaic brain injury exclusion criteria: * none

Keywords: injury
correlation between driver gene abnormalities and clinicopathological characteristics and disease prognosis in lymphoma

Conditions: Lymphoma; Gene Abnormality

Summary: correlation between driver gene abnormalities and clinicopathological characteristics and disease prognosis in lymphoma

this trial is a prospective non-interventional observational study. the chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.

Eligibility criteria:
inclusion criteria: 1. diagnosed as lymphoma (according to who 2017 classification criteria) 2. life expectancy no less than 3 months 3. agreeing to sign the written informed consents exclusion criteria: 1. other malignant tumor history or active malignant tumor need be treated 2. researchers determine unsuited to participate in this trial

Keywords: lymphoma driver gene abnormalities disease prognosis
mirtazapine for the treatment of methamphetamine dependence among msm (m2.0)

Conditions: Amphetamine-Related Disorders

Summary: the investigators recently conducted a double-blind, randomized controlled trial (n=60) of limited duration (12 weeks), and found that compared with placebo, oral mirtazapine, an fda-approved antidepressant, significantly reduced meth use in those receiving mirtazapine, as determined by reduction in meth-positive urines. sexual risk behaviors also declined significantly in the mirtazapine arm compared to placebo. mirtazapine decreased meth use despite low adherence: by medical event monitoring system (mems) caps, only 48.5% of daily doses were taken. all participants received weekly substance use counseling and monthly, brief clinician-delivered adherence counseling. the investigators propose expanding upon these results by lengthening the treatment period to 24 weeks, with adherence reminders added to the counseling, and determining if efficacy is sustained up to 12 weeks after drug discontinuation. the sample size for this 9-month study is 120.


Eligibility criteria:
inclusion criteria: 1. born male, or born female and does not identify as female; 2. reports anal sex with men in the prior three months while under the influence of meth; 3. diagnosed with meth dependence by scid; 4. interested in stopping or reducing meth use; 5. at least one meth-positive urine during screening and run-in period; 6. no current acute illness requiring prolonged medical care; 7. no serious chronic illnesses that are likely to progress clinically during trial participation; 8. able and willing to provide informed consent and adhere to visit schedule; 9. age 18-69 years; 10. baseline cbc, total protein, albumin, glucose, alkaline phosphatase, creatinine, bun, and electrolytes without clinically significant abnormalities as determined by clinician in conjunction with symptoms, physical exam, and medical history 11. current cd4 count ≥ 200 cells/mm3; or cd4 count of 100 - 199 cells/mm3 and hiv viral load \< 200 copies/ml 12. text-capable cell phone or access to email exclusion criteria: 1. evidence of current major depression by scid; 2. history of bipolar disorder or psychotic disorder, as determined by scid; 3. known allergy or previous adverse reaction to mirtazapine; 4. taking an anti-depressant medication within the past 30 days, including mirtazapine or a monoamineoxidase inhibitor; 5. moderate or severe liver disease (ast, alt, and total bilirubin \>= 5 times upper limit of normal); 6. impaired renal function (estimated gfr \<40 ml/min); 7. currently participating in another research study; 8. pending legal proceedings with high risk for incarceration during the time of planned study participation; 9. any condition that, in the principal investigator's judgment, interferes with safe study participation or adherence to study procedures.

Keywords: hiv sexual behavior
prospective observational multicenter study of patients with ah and ckd markers in kazakhstan (progress-ckd)

Conditions: Rate of CKD Diagnosis in Patients With AH and CKD Markers; Demographic and Clinical Characteristics for Those Patients; Routine Therapy Before and After the Diagnosis of CKD

Summary: multicenter, non-interventional prospective observational study with retrospective analysis to describe the rate of ckd diagnosis in patients with arterial hypertension and ckd markers in kazakhstan

primary endpoints: the proportion of patients with markers of chronic kidney disease (ckd) among patients with arterial hypertension such as: albuminuria/proteinuria; gfr \<60 ml/min/1.73 m2 (cfr categories c3a-c5). secondary endpoints: the following secondary endpoints will be evaluated in all patients with ah and markers of ckd included in the study (full analysis sampling - fas) (secondary aim 1) and in the subgroup of patients with a diagnosis of ckd confirmed during the study (modified full analysis sampling - mfas), i.e., at visit 1 or visit 2 (secondary aim 2):

Eligibility criteria:
inclusion criteria: age ≥18 years at the time of inclusion; * patient signed and dated written informed consent form (icf) in accordance with ich gcp and local legislation prior to inclusion in the study for the prospective observational cohort; * established diagnosis of hypertension, diagnosed in accordance with current clinical guidelines for hypertension, i.e. in adults, i.e. systolic blood pressure (sbp) ≥140 mmhg and/or diastolic blood pressure (dbp) ≥90 mmhg. when measured at two different visits * laboratory markers of ckd (egfr \<60 ml/min/1.73 m2 and/or albuminuria/proteinuria\*) measured during the period ≥3 and ≤12 months prior to inclusion in the study without a recorded diagnosis of ckd in the primary medical record prior to inclusion; \* any of the following: urine albumin/creatinine ratio (uacr) ≥30 mg/g (3 mg/mmol), urine total protein(protein)/creatinine ratio ≥150 mg/g (15 mg/mmol), albuminuria ≥30 mg/d or proteinuria ≥0.15 mg/d. * absence of documented diagnosis of ckd in the patient's medical records prior to inclusion in the study exclusion criteria: * absence of a signed icf in patients in the prospective follow-up group * participation in any randomized controlled trial within 3 months prior to inclusion in this study or during participation in this study * an established diagnosis of type 1 or type 2 diabetes mellitus. * diagnosis of symptomatic chronic heart failure (chf), nyha functional class iii-iv, documented in the patient's medical records * diagnosis of ah of secondary genesis
a phase 2 study to evaluate al001 in c9orf72-associated als

Conditions: Amyotrophic Lateral Sclerosis

Summary: a phase 2 double-blind, placebo-controlled study of al001 in participants with c9orf72-associated als.

this is a phase 2 double-blind, placebo-controlled trial to test the safety, tolerability, pharmacokinetics, and pharmacodynamics of al001 in participants with c9orf72-associated amyotrophic lateral sclerosis.

Eligibility criteria:
inclusion criteria: * confirmation of c9orf72 mutation * diagnosis of als by revised el escorial criteria * time since onset of muscle weakness due to als ≤36 months at the time of the screening visit * slow vital capacity (vc) ≥50% of predicted capacity at the time of the screening visit * if taking riluzole, must be on a stable dose of riluzole for at least 30 days prior to the screening visit. riluzole naive participants are allowed. * if taking edaravone, must have completed at least one cycle of edaravone prior to the screening visit and plan to continue edaravone during the study. edaravone naive participants are allowed. * females must not be pregnant, breastfeeding or planning to conceive within the study period. males must agree to use acceptable contraception * capable of providing informed consent at the screening visit and complying with study procedures throughout the study exclusion criteria: * clinically significant, unstable, medical condition (other than als) * clinically significant heart disease, liver disease or kidney disease * cognitive impairment or dementia * current uncontrolled hypertension * history of unresolved cancer * any experimental gene therapy * any experimental vaccine (any vaccine against covid-19 either approved or administered under an emergency use authorization is allowed)
endometrioma related reduced ovarian reserve

Conditions: Endometriosis

Summary: prior studies have shown surgical excision of endometriomas are associated with a decline in ovarian reserve as assessed by serum anti-mullerian hormone (amh) levels. however, the natural history of serum amh levels in the presence of untreated endometriomas are unknown. purpose of this study is to determine whether the presence of endometriomas cause a faster decline in serum amh levels than in healthy women over a six months period.

the study is a prospective cohort study. women diagnosed with endometriomas by transvaginal or transabdominal ultrasound or mri will be recruited from a tertiary care endometriosis clinic. age matched healthy controls will be recruited from the staff of the same hospital. a priorly published historical group of women who underwent endometrioma excision will be a second comparator.

Eligibility criteria:
inclusion criteria: * reproductive age * endometrioma without indication for surgery or treatment with combined contraceptive, progestin or other hormonal intervention. exclusion criteria: * menstrual cycle irregularity * polycystic ovarian syndrome * women who were pregnant or contemplating pregnancy in the next six months * history of ovarian surgery * using medication which could affect ovarian function during six months before recruitment * indication for surgical excision

Keywords: ovarian endometriomas amh ovarian reserve